San Francisco Office to Partner with UCSF Medical Center
We are pleased to announce that as of March 2016, the Lenox Hill TMS San Francisco center is partnering with the University of California- San Francisco Medical Center. This collaboration will now make TMS accessible to more patients suffering from depression in the greater San Francisco area. The doctors and staff at Lenox Hill TMS will provide onsite Transcranial Magnetic Stimulation therapy training to UCSF physicians while providing our facility to treat UCSF patients. We will also be providing TMS education to the UCSF Medical School and Psychiatry Residency Program.
Psychiatry Grand Rounds Presentation at CPMC
Roberto Estrada, M.D. was honored to give a Grand Rounds Presentation on, “Interventional Psychiatry: Brain Stimulation Therapies in Major Depressive Disorder and other Neuropsychiatric Disorders,” for the Department of Psychiatry at the California Pacific Medical Center- Sutter Health on December 8, 2015. The talk was well-received and appreciated by the attendees.
Lenox Hill TMS to Expand in the Bay Area
Our mission at Lenox Hill TMS has always been to increase access to and awareness of Transcranial Magnetic Treatment therapy for the millions of Americans affected by severe depression. Lenox Hill TMS San Francisco is looking at partnering with psychiatrists in the Bay Area to open new locations in the Financial District, Palo Alto, San Mateo and the East Bay, to better serve our patients in the Bay area. Contact us at: info@LenoxHIllTMS.com if you are interested in partnership opportunities.
International Psychiatric Conferences
Dr. Bryan Bruno and Dr. Robert Estrada, attended important conferences in the field of Brain Stimulation and TMS including: the International Society for ECT and Neurostimulation, the Clinical TMS Society Meeting and the American Psychiatric Association Annual Conference from May 15-20, 2015 in Toronto, CA.
Welcoming a New TMS Coordinator in NY Office
We are happy to welcome Andre McClendon to the Lenox Hill TMS New York office. “Before joining the Lenox Hill team, I worked as a TMS Coordinator for over 2 years in Florida. Being involved with so many different types of cases and seeing how patients benefit from TMS in their own way has really made me appreciate what I do; It’s a humbling honor seeing patients smile again.”
TMS Treatment of MDD in Pregnancy
12th World Congress of Biological Psychiatry June 16, 2015
Transcranial Magnetic Stimulation (TMS) significantly reduces symptoms of Major Depressive Disorder during pregnancy and appears to be a safe and effective alternative to antidepressants for women who do not wish to take medication while pregnant, new research shows.
The study involved 12 women treated with active TMS and another 10 treated with sham TMS. All women had major depressive disorder (MDD) and were from 14 to 34 weeks’ gestation. Patients received 20 sessions of right-sided TMS delivered to the right dorsolateral prefrontal cortex at a dose of 1 Hz in a 15-minute train at 100% motor threshold (900 pulses/session) or the same number of sessions of sham TMS. Nine of the 12 women (75%) who received active TMS responded to treatment at the end of the 20-session protocol, as did five of 10 women (50%) who received sham TMS.
Response was higher in the active coil group, as reflected by a lower Hamilton Depression Rating Scale score at the end of the 20-session protocol, at 9.8 vs 12.9 for those in the sham TMS group. Adverse events from the magnetic effect from TMS would not be expected because the magnet only influences a 2×2-cm area of the cortex and so comes nowhere near the uterus, according to study investigator Deborah Kim, MD, Assistant Professor of Psychiatry, University of Pennsylvania, in Philadelphia.
“This is really an acceptability issue,” said Dr. Kim. “Women say that they prefer psychotherapy over medication, but access to psychotherapy and its cost limit its use, and the fact that not everybody responds to psychotherapy means we need something else…” she said, “and TMS is good for pregnant women with moderate to severe depression who don’t want to take antidepressants.
New TMS Devices Approved by the FDA
Magstim’s Rapid 2 TMS System and Magventure’s MagVita TMS System are now part of four devices including Neuronetics NeuroStar TMS System and the Brainsway TMS System that are cleared by the FDA to treat Major Depressive Disorder.
Insurance Coverage for TMS
We and are encouraged to report that the following insurance carriers have TMS coverage policies: